



SKYWAY XPRO

Version 7 / IRL
102000014326

1/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier

Trade name SKYWAY XPRO
UFI Y9G0-80MQ-5003-KNSV
Product code (UVP) 79053649, 86197928

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use Fungicide

1.3 Details of the supplier of the safety data sheet

Supplier Bayer CropScience Ltd
Bayer Ltd
1st Floor, The Grange Offices
The Grange, Brewery Road
Stillorgan
A94 H2K7 Co. Dublin
Ireland

Telephone +353 1 216 3300

Responsible Department Email: gb-bcs-crop-regulatory-affairs@bayer.com

1.4 Emergency telephone no.

Emergency telephone no. +44 330 678 3382 (24 hr) (charged as a standard international call to the UK)

For Medical Professionals and Members of the Public:
You can also contact the relevant NPIS.

National Poisons Information Centre Dublin: 01 809 2166

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Classification in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Acute toxicity: Category 4
H302 Harmful if swallowed.

Skin sensitisation: Category 1
H317 May cause an allergic skin reaction.

Specific target organ toxicity - single exposure: Category 3



SKYWAY XPRO

Version 7 / IRL
102000014326

2/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

H335 May cause respiratory irritation.
Reproductive toxicity: Category 2
H361d Suspected of damaging the unborn child.
Short-term (acute) aquatic hazard: Category 1
H400 Very toxic to aquatic life.
Long-term (chronic) aquatic hazard: Category 1
H410 Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Hazard label for supply/use required.

Hazardous components which must be listed on the label:

- Bixafen
- Prothioconazole
- Tebuconazole
- N,N-Dimethyl decanamide



Signal word: Warning

Hazard statements

H302 Harmful if swallowed.
H317 May cause an allergic skin reaction.
H335 May cause respiratory irritation.
H361d Suspected of damaging the unborn child.
H410 Very toxic to aquatic life with long lasting effects.
EUH401 To avoid risks to human health and the environment, comply with the instructions for use.

Precautionary statements

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor/ physician.
P410 Protect from sunlight.
P501 Dispose of contents/container to a licensed hazardous waste disposal contractor or collection site, except for triple rinsed empty containers which can be disposed of as non-hazardous waste.

2.3 Other hazards

No additional hazards known beside those mentioned.

Tebuconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
Prothioconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
Bixafen: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
2-Ethylhexanol propylene ethyleneglycol ether: Not applicable
N,N-Dimethyldecanamide: This substance is not considered to be



SKYWAY XPRO

Version 7 / IRL
102000014326

3/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.2 Mixtures

Chemical nature

Emulsifiable concentrate (EC)
Bixafen 75 g/l, Prothioconazole 100 g/l, Tebuconazole 100 g/l

Hazardous components

Hazard statements according to Regulation (EC) No. 1272/2008

Name	CAS-No. / EC-No. / REACH Reg. No.	Classification	Conc. [%]
		REGULATION (EC) No 1272/2008	
Bixafen	581809-46-3	Aquatic Acute 1, H400 Aquatic Chronic 1, H410	7.4
Prothioconazole	178928-70-6	Aquatic Acute 1, H400 Aquatic Chronic 1, H410	9.9
Tebuconazole	107534-96-3 403-640-2	Acute Tox. 4, H302 Repr. 2, H361d Aquatic Acute 1, H400 Aquatic Chronic 1, H410	9.9
2-Ethylhexanol propylene ethyleneglycol ether	64366-70-7	Aquatic Chronic 3, H412	> 1 – < 25
N,N-Dimethyl decanamide	14433-76-2 238-405-1 01-2119485027-36-XXXX	Skin Irrit. 2, H315 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	> 25

Further information

Bixafen	581809-46-3	M-Factor: 10 (acute)
Prothioconazole	178928-70-6	M-Factor: 10 (acute), 1 (chronic)
Tebuconazole	107534-96-3	M-Factor: 1 (acute), 10 (chronic)

For the full text of the H-Statements mentioned in this Section, see Section 16.

Particle characteristics

This substance/ mixture does not contain nanoforms



SKYWAY XPRO

Version 7 / IRL
102000014326

4/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

SECTION 4: FIRST AID MEASURES

4.1 Description of first aid measures

General advice	Move out of dangerous area. Place and transport victim in stable position (lying sideways). Remove contaminated clothing immediately and dispose of safely.
Inhalation	Move to fresh air. Keep patient warm and at rest. Call a physician or poison control center immediately.
Skin contact	Wash off thoroughly with plenty of soap and water, if available with polyethyleneglycol 400, subsequently rinse with water. If symptoms persist, call a physician.
Eye contact	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eye. Get medical attention if irritation develops and persists.
Ingestion	Rinse mouth. Do NOT induce vomiting. Call a physician or poison control center immediately.

4.2 Most important symptoms and effects, both acute and delayed

Symptoms	No symptoms known or expected.
-----------------	--------------------------------

4.3 Indication of any immediate medical attention and special treatment needed

Treatment	Treat symptomatically. In case of ingestion gastric lavage should be considered in cases of significant ingestions only within the first 2 hours. However, the application of activated charcoal and sodium sulphate is always advisable. There is no specific antidote.
------------------	--

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable	Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Unsuitable	High volume water jet

5.2 Special hazards arising from the substance or mixture	In the event of fire the following may be released:; Hydrogen chloride (HCl), Hydrogen cyanide (hydrocyanic acid), Hydrogen fluoride, Carbon monoxide (CO), Sulphur oxides, Nitrogen oxides (NOx)
--	---

5.3 Advice for firefighters

Special protective equipment for firefighters	In the event of fire and/or explosion do not breathe fumes. In the event of fire, wear self-contained breathing apparatus.
Further information	Contain the spread of the fire-fighting media. Do not allow run-off from fire fighting to enter drains or water courses.



SKYWAY XPRO

Version 7 / IRL
102000014326

5/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Precautions Avoid contact with spilled product or contaminated surfaces. Use personal protective equipment.

6.2 Environmental precautions Do not allow to get into surface water, drains and ground water. If the product contaminates rivers and lakes or drains inform respective authorities.

6.3 Methods and materials for containment and cleaning up

Methods for cleaning up Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust). Clean contaminated floors and objects thoroughly, observing environmental regulations. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections Information regarding safe handling, see section 7.
Information regarding personal protective equipment, see section 8.
Information regarding waste disposal, see section 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Advice on safe handling No specific precautions required when handling unopened packs/containers; follow relevant manual handling advice. Ensure adequate ventilation.

Advice on protection against fire and explosion Keep away from heat and sources of ignition.

Hygiene measures Avoid contact with skin, eyes and clothing. Keep working clothes separately. Wash hands before breaks and immediately after handling the product. Wash hands immediately after work, if necessary take a shower. Remove soiled clothing immediately and clean thoroughly before using again. Garments that cannot be cleaned must be destroyed (burnt).

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers Store in original container. Keep containers tightly closed in a dry, cool and well-ventilated place. Store in a place accessible by authorized persons only. Protect from freezing. Keep away from direct sunlight.

Suitable materials Coextruded containers with an internal barrier layer made of ethylene vinyl alcohol copolymer (EVOH)

7.3 Specific end use(s) Refer to the label and/or leaflet.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components	CAS-No.	Control parameters	Update	Basis
------------	---------	--------------------	--------	-------



SKYWAY XPRO

Version 7 / IRL
102000014326

6/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

Tebuconazole	107534-96-3	0.2 mg/m ³ (SK-ABS)		OES BCS*
Prothioconazole	178928-70-6	1.4 mg/m ³ (SK-ABS)		OES BCS*
Bixafen	581809-46-3	0.6 mg/m ³ (TWA)		OES BCS*

*OES BCS: Internal Bayer AG, Crop Science Division "Occupational Exposure Standard"

8.2 Exposure controls

Personal protective equipment

Formulated product

Respiratory protection

Wear respirator with an organic vapours and gas filter mask (protection factor 10) conforming to EN140 type A or equivalent. Respiratory protection should only be used to control residual risk of short duration activities, when all reasonably practicable steps have been taken to reduce exposure at source e.g. containment and/or local extract ventilation. Always follow respirator manufacturer's instructions regarding wearing and maintenance.

Hand protection

Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. Also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion, and the contact time.

Wash gloves when contaminated. Dispose of when contaminated inside, when perforated or when contamination on the outside cannot be removed. Wash hands frequently and always before eating, drinking, smoking or using the toilet.

Material	Nitrile rubber
Rate of permeability	> 480 min
Glove thickness	> 0.4 mm
Protective index	Class 6
Directive	Protective gloves complying with EN 374.

Eye protection

Wear goggles (conforming to EN166, Field of Use = 5 or equivalent).

Skin and body protection

Wear standard coveralls and Category 3 Type 4 suit. If there is a risk of significant exposure, consider a higher protective type suit.

Wear two layers of clothing wherever possible. Polyester/cotton or cotton overalls should be worn under chemical protection suit and should be professionally laundered frequently.

If chemical protection suit is splashed, sprayed or significantly contaminated, decontaminate as far as possible, then carefully remove and dispose of as advised by manufacturer.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties



SKYWAY XPRO

Version 7 / IRL
102000014326

7/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

Form	Liquid, clear to slightly turbid
Colour	yellow to brown
Odour	aromatic
Odour Threshold	No data available
Melting point/ range	No data available
Boiling Point	No data available
Flammability	No data available
Upper explosion limit	No data available
Lower explosion limit	No data available
Flash point	> 103 °C
Auto-ignition temperature	No data available
Ignition temperature	370 °C
Self-accelarating decomposition temperature (SADT)	No data available
pH	4.5 - 6.5 (1 %) (23 °C) (deionized water)
Viscosity, dynamic	No data available
Viscosity, kinematic	101 mm ² /s (20 °C) Shear rate of 100/sec
Water solubility	miscible
Partition coefficient: n-octanol/water	Tebuconazole: log Pow: 3.7 Prothioconazole: log Pow: 3.82 (20 °C) (pH 7) Bixafen: log Pow: 3.3 (40 °C) 2-Ethylhexanol propylene ethyleneglycol ether: No data available N,N-Dimethyldecanamide: log Pow: 2.46
Surface tension	27 mN/m (25 °C) Determined in the undiluted form.
Vapour pressure	No data available
Density	ca. 1.01 g/cm ³ (20 °C)
Relative density	No data available
Relative vapour density	No data available
Assessment nano particles	This substance/ mixture does not contain nanoforms
Particle size	No data available

9.2 Other information



SKYWAY XPRO

Version 7 / IRL
102000014326

8/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

Explosivity	Not explosive
Oxidizing properties	No oxidizing properties
Evaporation rate	No data available
Other physico-chemical properties	Further safety related physical-chemical data are not known.

SECTION 10: STABILITY AND REACTIVITY

10.1 Reactivity	Stable under normal conditions.
10.2 Chemical stability	Stable under recommended storage conditions.
10.3 Possibility of hazardous reactions	No hazardous reactions when stored and handled according to prescribed instructions.
10.4 Conditions to avoid	Extremes of temperature and direct sunlight.
10.5 Incompatible materials	Store only in the original container.
10.6 Hazardous decomposition products	No decomposition products expected under normal conditions of use.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on hazard classes as defined in regulation (EC) No 1272/2008

Acute oral toxicity	LD50 (Rat) 550 - 2,000 mg/kg
Acute inhalation toxicity	During intended and foreseen applications, no respirable aerosol is formed. Irritating to respiratory system. The value mentioned relates to N,N-dimethylacetamide.
Acute dermal toxicity	LD50 (Rat) > 2,000 mg/kg No deaths
Skin corrosion/irritation	No skin irritation (Rabbit)
Serious eye damage/eye irritation	No eye irritation (Rabbit)
Respiratory or skin sensitisation	Skin: Sensitising (Mouse) OECD Test Guideline 429, local lymph node assay (LLNA)

Assessment STOT Specific target organ toxicity – single exposure

Tebuconazole: Based on available data, the classification criteria are not met.
Prothioconazole: Based on available data, the classification criteria are not met.
Bixafen: Based on available data, the classification criteria are not met.



SKYWAY XPRO

Version 7 / IRL
102000014326

9/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

2-Ethylhexanol propylene ethyleneglycol ether: Based on available data, the classification criteria are not met.

N,N-Dimethyldecan-1-amide: May cause respiratory irritation.

Assessment STOT Specific target organ toxicity – repeated exposure

Tebuconazole did not cause specific target organ toxicity in experimental animal studies.

Prothioconazole did not cause specific target organ toxicity in experimental animal studies.

Bixafen did not cause human relevant specific target organ toxicity in experimental animal studies.

2-Ethylhexanol propylene ethyleneglycol ether: Based on available data, the classification criteria are not met.

N,N-Dimethyldecanamide did not cause specific target organ toxicity in experimental animal studies.

Assessment mutagenicity

Tebuconazole was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

Prothioconazole was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.

Bixafen was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

2-Ethylhexanol propylene ethyleneglycol ether is not considered mutagenic.

N,N-Dimethyldecanamide was not genotoxic in a battery of in vitro tests.

Assessment carcinogenicity

Tebuconazole caused at high dose levels an increased incidence of tumours in mice in the following organ(s): Liver. The mechanism of tumour formation is not considered to be relevant to man.

Prothioconazole was not carcinogenic in lifetime feeding studies in rats and mice.

Bixafen was not carcinogenic in lifetime feeding studies in rats and mice.

2-Ethylhexanol propylene ethyleneglycol ether: Based on available data, the classification criteria are not met.

N,N-Dimethyldecanamide is not considered carcinogenic.

Assessment toxicity to reproduction

Tebuconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Tebuconazole is related to parental toxicity.

Prothioconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Prothioconazole is related to parental toxicity.

Bixafen did not cause reproductive toxicity in a two-generation study in rats.

2-Ethylhexanol propylene ethyleneglycol ether: Based on available data, the classification criteria are not met.

N,N-Dimethyldecanamide is not considered a reproductive toxicant at non-maternally toxic dose levels.

Assessment developmental toxicity

Tebuconazole caused developmental toxicity only at dose levels toxic to the dams. Tebuconazole caused an increased incidence of post implantation losses, an increased incidence of non-specific malformations.

Prothioconazole caused developmental toxicity only at dose levels toxic to the dams. The developmental effects seen with Prothioconazole are related to maternal toxicity.

Bixafen did not cause developmental toxicity in rats and rabbits.

2-Ethylhexanol propylene ethyleneglycol ether: This information is not available.

N,N-Dimethyldecanamide did not cause developmental toxicity in rats and rabbits.

Aspiration hazard

Based on available data, the classification criteria are not met.

Further information



SKYWAY XPRO

Version 7 / IRL
102000014326

10/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

No further toxicological information is available.

11.2 Information on other hazards

Endocrine disrupting properties

Assessment

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity

Toxicity to fish

LC50 (Oncorhynchus mykiss (rainbow trout)) 1.55 mg/l
Exposure time: 96 h

Toxicity to aquatic invertebrates

EC50 (Daphnia magna (Water flea)) 5.5 mg/l
Exposure time: 48 h

Chronic toxicity to aquatic invertebrates

NOEC (Daphnia (water flea)): 0.01 mg/l
Exposure time: 21 d
The value mentioned relates to the active ingredient tebuconazole.

Toxicity to aquatic plants

IC50 (Raphidocelis subcapitata (freshwater green alga)) 1.93 mg/l
Growth rate; Exposure time: 72 h
ErC50 (Skeletonema costatum) 0.03278 mg/l
Exposure time: 72 h
The value mentioned relates to the active ingredient prothioconazole.
EC10 (Skeletonema costatum) 0.01427 mg/l
Growth rate; Exposure time: 72 h
The value mentioned relates to the active ingredient prothioconazole.
(Lemna gibba (gibbous duckweed)) 0.237 mg/l
Growth rate; Exposure time: 7 d
The value mentioned relates to the active ingredient tebuconazole.

12.2 Persistence and degradability

Biodegradability

Tebuconazole:
Not rapidly biodegradable
Prothioconazole:
Not rapidly biodegradable
Bixafen:
Not rapidly biodegradable
2-Ethylhexanol propylene ethyleneglycol ether:
Not readily biodegradable.
N,N-Dimethyldecanamide:
rapidly biodegradable

Koc

Tebuconazole: Koc: 769
Prothioconazole: Koc: 1765



SKYWAY XPRO

Version 7 / IRL
102000014326

11/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

Bixafen: Koc: 3869
2-Ethylhexanol propylene ethyleneglycol ether: No data available

12.3 Bioaccumulative potential

Bioaccumulation

Tebuconazole: Bioconcentration factor (BCF) 35 - 59
Does not bioaccumulate.
Prothioconazole: Bioconcentration factor (BCF) 19
Does not bioaccumulate.
Bixafen: Bioconcentration factor (BCF) 695
Does not bioaccumulate.
2-Ethylhexanol propylene ethyleneglycol ether:
No data available
N,N-Dimethyldecanamide:
Does not bioaccumulate.

12.4 Mobility in soil

Mobility in soil

Tebuconazole: Slightly mobile in soils
Prothioconazole: Slightly mobile in soils
Bixafen: Slightly mobile in soils
2-Ethylhexanol propylene ethyleneglycol ether: No data available
N,N-Dimethyldecanamide: Slightly mobile in soils

12.5 Results of PBT and vPvB assessment

PBT and vPvB assessment

Tebuconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
Prothioconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
Bixafen: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
2-Ethylhexanol propylene ethyleneglycol ether: Not applicable
N,N-Dimethyldecanamide: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).

12.6 Endocrine disrupting properties

Assessment

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

Additional ecological information

No other effects to be mentioned.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods



SKYWAY XPRO

Version 7 / IRL
102000014326

12/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

Product	It is best to use all of the product in accordance with label directions. If it is necessary to dispose of unused product, please follow container label instructions and applicable local guidelines.
Contaminated packaging	Small containers (< 10 l or < 10 kg) should be rinsed thoroughly using an integrated pressure rinsing device, or, by manually rinsing three times. Add washings to sprayer at time of filling. Dispose of empty and cleaned packaging safely. Follow advice on product label and/or leaflet.
Waste key for the unused product	02 01 08* agrochemical waste containing hazardous substances

SECTION 14: TRANSPORT INFORMATION

ADR/RID/ADN

14.1 UN number	3082
14.2 Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (BIXAFEN SOLUTION)
14.3 Transport hazard class(es)	9
14.4 Packing group	III
14.5 Environm. Hazardous Mark	YES
Hazard no.	90
Tunnel Code	-

This classification is in principle not valid for carriage by tank vessel on inland waterways. Please refer to the manufacturer for further information.

IMDG

14.1 UN number	3082
14.2 Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (BIXAFEN SOLUTION)
14.3 Transport hazard class(es)	9
14.4 Packing group	III
14.5 Marine pollutant	YES

IATA

14.1 UN number	3082
14.2 Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (BIXAFEN SOLUTION)
14.3 Transport hazard class(es)	9
14.4 Packing group	III
14.5 Environm. Hazardous Mark	YES

14.6 Special precautions for user

See sections 6 to 8 of this Safety Data Sheet.

14.7 Transport in bulk according to IMO instruments

No transport in bulk according to the IBC Code.



SKYWAY XPRO

Version 7 / IRL
102000014326

13/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Republic of Ireland Regulations

This material may be subject to some or all of the following regulations (and any subsequent amendments). Users must ensure that any uses and restrictions as indicated on the label and/or leaflet are followed.

Supply and Use

European Communities (Prohibition of Certain Active Substances in Plant Protection Products) Regulations 1981 (SI No 320/1981)
European Communities (Authorization, Placing on the Market, Use and Control of Plant Protection Products) Regulations 2003 (SI No 83/2003)
European Communities (Classification, Packaging and Labelling of Plant Protection Products and Biocide Products) Regulations 2001 (SI No 624/2001)
2010 Code of Practice for the Safety, Health and Welfare at Work (Chemical Agents) Regulations, 2001 (SI No 619/2001)

Waste Treatment

Landfill Directive
Regulation on Substances That Deplete the Ozone Layer 1994 (EEC/3093/94)

Further information

WHO-classification: II (Moderately hazardous)

15.2 Chemical safety assessment

A chemical safety assessment is not required.

SECTION 16: OTHER INFORMATION

Text of the hazard statements mentioned in Section 3

H302	Harmful if swallowed.
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H361d	Suspected of damaging the unborn child.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.

Abbreviations and acronyms

ADN	European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways
ADR	European Agreement concerning the International Carriage of Dangerous Goods by Road
ATE	Acute toxicity estimate
CAS-Nr.	Chemical Abstracts Service number



SKYWAY XPRO

Version 7 / IRL
102000014326

14/14

Revision Date: 11.12.2024
Print Date: 17.03.2025

Conc.	Concentration
EC-No.	European community number
ECx	Effective concentration to x %
EINECS	European inventory of existing commercial substances
ELINCS	European list of notified chemical substances
ELV	Exposure Limit Value
EN	European Standard
EU	European Union
IATA	International Air Transport Association
IBC	International Code for the Construction and Equipment of Ships Carrying Dangerous Chemicals in Bulk (IBC Code)
ICx	Inhibition concentration to x %
IMDG	International Maritime Dangerous Goods
LCx	Lethal concentration to x %
LDx	Lethal dose to x %
LOEC/LOEL	Lowest observed effect concentration/level
MARPOL	MARPOL: International Convention for the prevention of marine pollution from ships
N.O.S.	Not otherwise specified
NOEC/NOEL	No observed effect concentration/level
OECD	Organization for Economic Co-operation and Development
RID	Regulations concerning the International Carriage of Dangerous Goods by Rail
SI	Statutory Instrument
TWA	Time weighted average
UN	United Nations
WHO	World health organisation

The information contained within this Safety Data Sheet is in accordance with the guidelines established by Regulation (EU) 1907/2006 and Regulation (EU) 2020/878 amending Regulation (EU) No 1907/2006 and any subsequent amendments. This data sheet complements the user's instructions, but does not replace them. The information it contains is based on the knowledge available about the product concerned at the time it was compiled. Users are further reminded of the possible risks of using a product for purposes other than those for which it was intended. The required information complies with current EEC legislation. Addressees are requested to observe any additional national requirements.

Reason for Revision: The following sections have been revised: Section 2: Hazards Identification. Section 3: Composition / Information on Ingredients. Section 16: Other Information.

Changes since the last version are highlighted in the margin. This version replaces all previous versions.